Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects with Idiopathic Parkinson's Disease

Sponsor ID

20020168

Clinicaltrials.gov ID

NCT00115427

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.

Additional Study Details

Phase

Phase 1

Product

liatermin

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Protocol Summary

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Locations

No locations found.